




PHARMACEUTICAL 2023

Catalent Inc.
Rank 200 of 446





PHARMACEUTICAL 2023

Catalent Inc.
Rank 200 of 446



The relative strengths and weaknesses of Catalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Catalent Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Catalent Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is 108%, being 64% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,916,000
Cost of Goods Sold	3,188,000
Intangible Assets	4,066,000
Liabilities, Current	1,072,000
Liabilities, Non-Current	164,000
Other Assets	398,000
Other Compr. Net Income	-77,000
Other Expenses	127,000
Other Liabilities	4,476,000
Other Net Income	-150,000
Other Revenues	4,828,000
Property and Equipment	3,127,000
Research and Development	0
Selling, General and Administrative Expense	844,000

Output Variable	Value in 1000 USD
Assets	10,507,000
Liabilities	5,712,000
Expenses	4,159,000
Revenues	4,828,000
Stockholders Equity	4,795,000
Net Income	519,000
Comprehensive Net Income	480,500
Economic Capital Ratio	108%